Barclays PLC Purchases 35,950 Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)

Barclays PLC boosted its position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) by 13.0% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 312,560 shares of the biotechnology company's stock after acquiring an additional 35,950 shares during the quarter. Barclays PLC owned 0.25% of Arrowhead Pharmaceuticals worth $5,876,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in ARWR. R Squared Ltd bought a new position in shares of Arrowhead Pharmaceuticals in the fourth quarter worth about $38,000. Van ECK Associates Corp boosted its position in Arrowhead Pharmaceuticals by 72.3% in the fourth quarter. Van ECK Associates Corp now owns 2,978 shares of the biotechnology company's stock valued at $56,000 after buying an additional 1,250 shares in the last quarter. KBC Group NV grew its stake in shares of Arrowhead Pharmaceuticals by 45.9% during the fourth quarter. KBC Group NV now owns 5,224 shares of the biotechnology company's stock worth $98,000 after buying an additional 1,644 shares during the last quarter. Envestnet Portfolio Solutions Inc. acquired a new position in shares of Arrowhead Pharmaceuticals during the fourth quarter worth $190,000. Finally, First Citizens Bank & Trust Co. acquired a new stake in shares of Arrowhead Pharmaceuticals during the 4th quarter valued at $205,000. 62.61% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several equities research analysts recently commented on ARWR shares. HC Wainwright reiterated a "buy" rating and set a $80.00 target price on shares of Arrowhead Pharmaceuticals in a research report on Wednesday, February 12th. Chardan Capital reiterated a "buy" rating and issued a $60.00 price target on shares of Arrowhead Pharmaceuticals in a research report on Tuesday, February 11th. Royal Bank of Canada restated an "outperform" rating and set a $42.00 price objective on shares of Arrowhead Pharmaceuticals in a research report on Tuesday, February 11th. Finally, B. Riley reiterated a "buy" rating and issued a $38.00 target price (down from $51.00) on shares of Arrowhead Pharmaceuticals in a report on Friday, February 14th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and six have given a buy rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Hold" and an average target price of $41.44.

Insider Activity

In other Arrowhead Pharmaceuticals news, CEO Christopher Richard Anzalone sold 51,425 shares of the business's stock in a transaction dated Thursday, March 13th. The stock was sold at an average price of $15.07, for a total value of $774,974.75. Following the completion of the transaction, the chief executive officer now owns 4,062,377 shares of the company's stock, valued at approximately $61,220,021.39. The trade was a 1.25 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders have sold a total of 275,880 shares of company stock worth $4,034,037 over the last 90 days. 4.30% of the stock is currently owned by insiders.

Arrowhead Pharmaceuticals Trading Up 1.6 %

Shares of Arrowhead Pharmaceuticals stock traded up $0.23 during trading on Thursday, reaching $14.12. The company's stock had a trading volume of 314,019 shares, compared to its average volume of 1,444,309. The company has a quick ratio of 6.09, a current ratio of 6.09 and a debt-to-equity ratio of 7.27. The company has a market cap of $1.94 billion, a price-to-earnings ratio of -2.73 and a beta of 0.99. The firm's 50-day moving average is $14.15 and its two-hundred day moving average is $18.31. Arrowhead Pharmaceuticals, Inc. has a 52-week low of $9.57 and a 52-week high of $30.41.

Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report) last released its earnings results on Monday, February 10th. The biotechnology company reported ($1.39) EPS for the quarter, missing the consensus estimate of ($0.42) by ($0.97). On average, sell-side analysts anticipate that Arrowhead Pharmaceuticals, Inc. will post -2.42 earnings per share for the current year.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.